Dr. Gill is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000Fax+1 650-498-5840
Summary
- Dr. Harcharan Gill is an urologist in Palo Alto, CA and is affiliated with multiple hospitals in the area, including Stanford Health Care and VA Palo Alto Health Care System. He received his medical degree from University of Nairobi College of Health Sciences and has been in practice 40 years. He also speaks multiple languages, including Punjabi. He specializes in minimally invasive surgery and surgical oncology and is experienced in urologic oncology, minimally invasive urologic surgery, urologic trauma and reconstructive surgery, metabolic stone disease, and greenlight laser therapy for benign prostatic hyperplasia.
Education & Training
- University of Pennsylvania Health SystemResidency, Urology, 1987 - 1991
- University of Nairobi College of Health SciencesClass of 1977
Certifications & Licensure
- CA State Medical License 1992 - 2026
- PA State Medical License 1990 - 1992
- American Board of Urology Urology
Awards, Honors, & Recognition
- Kathryn Simmons Stamey Professorship Endowment 2014
- America's Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Quality of Life Following Radical Prostatectomy Start of enrollment: 2002 Sep 01
- Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study Start of enrollment: 2014 Feb 01
Publications & Presentations
PubMed
- Editorial Comment on "Aquablation at 4-years: Real World Data From the Largest Single-center Study With Associated Outcomes Follow-up".Harcharan S Gill
Urology. 2024-12-01 - 18 citationsCorrelation ofGa-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.Heying Duan, Lucia Baratto, Richard E Fan, Simon John Christoph Soerensen, Tie Liang
Journal of Nuclear Medicine. 2022-12-01 - 1 citationsBupivacaine local anesthetic to decrease opioid requirements after radical cystectomy: Does formulation matter?Bogdana Schmidt, Hriday P. Bhambhvani, Daniel R. Greenberg, Kris Prado, Steven L. Shafer
Urologic Oncology. 2021-06-01
Journal Articles
- Surgical Outcomes and Complications Associated with Presurgical Tyrosine Kinase Inhibition for Advanced Renal Cell Carcinoma (RCC)Harshman LC, Yu RJ, Allen GI, Srinivas S, Gill HS, Chung BI, Urol Oncol, 1/1/2013
- Prostate Specific Antigen: The Past, Present and FutureGill H, Wu J, Curr Urol, 1/1/2012
- Long-term Outcomes from a Prospective Trial of Stereotactic Body Radiotherapy for Low-risk Prostate CancerKing CR, Brooks JD, Gill H, Presti JC, Int J Radiat Oncol Biol Phys, 1/1/2012
- Join now to see all
Books/Book Chapters
Lectures
- Review on BPH, Plenary SessionSan Francisco - 1/1/2014
- Highlighs on Penile and Bladder Cancer Plenary SessionSan Diego - 1/1/2013
- Take Home Messages in Testes and Penile CancerSan Diego - 1/1/2013
- Join now to see all
Professional Memberships
- Member
Other Languages
- Punjabi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: